Unicycive Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US90466Y1038
USD
6.77
-0.21 (-3.01%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Research Solutions, Inc.
1847 Holdings LLC
Science 37 Holdings, Inc.
Coya Therapeutics, Inc.
Gaia, Inc.
Katapult Holdings, Inc.
Harte-Hanks, Inc.
Celularity, Inc.
Unicycive Therapeutics, Inc.
Network-1 Technologies, Inc
Benson Hill, Inc.

Why is Unicycive Therapeutics, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Unicycive Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Unicycive Therapeutics, Inc.
13.82%
1.11
858.07%
S&P 500
14.9%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-77.60%
EBIT Growth (5y)
-53.04%
EBIT to Interest (avg)
-28.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.71
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.60%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.02
EV to EBIT
-3.43
EV to EBITDA
-3.49
EV to Capital Employed
-21.86
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-81.92%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at USD -13.9 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -0.33

-3What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -29.83 MM

Here's what is working for Unicycive Therapeutics, Inc.

Net Profit
Higher at USD -13.9 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

EPS
Highest at USD -0.33
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Unicycive Therapeutics, Inc.

Operating Cash Flow
Lowest at USD -29.83 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)